Loading...
Longboard Pharmaceuticals, Inc.
LBPH•NASDAQ
Healthcare
Biotechnology
$59.98
$0.00(0.00%)

Over the last four quarters, Longboard Pharmaceuticals, Inc. achieved steady financial progress, growing revenue from $8000.00 in Q4 2023 to $0.00 in Q3 2024. Gross profit stayed firm with margins at N/A in Q3 2024 versus 88% in Q4 2023. Operating income totaled -$28.12M in Q3 2024, maintaining a N/A margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$28.12M. Net income dropped to -$24.54M, with EPS at -$0.63. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan